TBIO - トランスジェノミック （Translate Bio Inc.） トランスジェノミックTBIOのチャート
TBIOの企業情報
| symbol | TBIO |
|---|---|
| 会社名 | Transgenomic Inc （トランスジェノミック） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Translate Bio Inc. is a messenger RNA or mRNA therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform or MRT platform and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung MRT5005 is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization. トランスジェノミックは米国のバイオ企業。コネチカットとネブラスカ州の臨床検査室で心臓、神経、ミトコンドリア異常、がん疾患の遺伝子検査を行う。また、分子遺伝学研究と分子診断用の遺伝子解析システム「ウェ―ブ」を製造、販売するほか、他社の生体計測装置を販売。また、機器の据え付け、保守、技術サポ―トを提供。 sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation. |
| 本社所在地 | 12325 Emmet Street Omaha NE 68164 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 617-945-7361 |
| 設立年月日 | 35490 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | 37人 |
| url | www.transgenomic.com |
| nasdaq_url | https://www.nasdaq.com/symbol/tbio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -94.58100 |
| 終値（lastsale） | 8.8799 |
| 時価総額（marketcap） | 400853693.031 |
| 時価総額 | 時価総額（百万ドル） 347.59100 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 523.63600 |
| 当期純利益 | 当期純利益（百万ドル） -89.80400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Translate Bio Inc revenues was not reported. Net loss applicable to common stockholders increased 52% to $48.1M. Higher net loss reflects Change in fair value of contingent consi increase from $4.6M to $12.8M (expense) General and Administrative - Balancing increase of 51% to $9M (expense) Research and development - Balancing increase of 13% to $25.5M (expense). |
TBIOのテクニカル分析
TBIOのニュース
Telesis Bio gets $28 million in financing through preferred stock private placement 2023/05/31 21:57:17 Seeking Alpha
Telesis Bio (NASDAQ:TBIO) said Wednesday it has signed an agreement with institutional investors to provide the company with funding of $28.0 million through a private placement of…
Telesis Bio Announces First Commercial Shipment of BioXp Select DNA Cloning Kit 2023/05/22 16:00:00 Wallstreet:Online
New Kit Enables Automation of DNA Cloning on the BioXp System Beginning from Linear DNA, Further Expanding the Utility, Speed, and Impact of the BioXp Automated Molecular Biology Workstation SAN DIEGO, May 22, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the first commercial shipment of its BioXp
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit 2023/05/22 16:00:00 GlobeNewswire
New Kit Enables Automation of DNA Cloning on the BioXp® System Beginning from Linear DNA, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation New Kit Enables Automation of DNA Cloning on the BioXp® System Beginning from Linear DNA, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation
Telesis Bio Announces First Commercial Shipment of BioXp® NGS Library Prep Kit 2023/05/18 14:00:00 GlobeNewswire
New Kit Enables Automation of NGS Library Prep on the BioXp® System Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation New Kit Enables Automation of NGS Library Prep on the BioXp® System Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation
Telesis Bio Announces First Commercial Shipment of BioXp NGS Library Prep Kit 2023/05/18 14:00:00 Wallstreet:Online
New Kit Enables Automation of NGS Library Prep on the BioXp System Further Expanding the Utility, Speed, and Impact of the BioXp Automated Molecular Biology Workstation SAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the first commercial shipment of its BioXp NGS Library Prep kit for
Why GameStop Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket 2023/03/22 12:07:20 Benzinga
Gainers Virgin Orbit Holdings, Inc. (NASDAQ: VORB ) shares rose 81.2% to $0.8032 in pre-market trading. Richard Branson''s Virgin Orbit is nearing a deal for a $200 million investment from Texas-based Venture Capital investor Matthew Brown via a private share placement, according to a term sheet. GameStop Corp. (NYSE: GME ) climbed 43.7% to $25.37 in pre-market trading after the company reported better-than-expected Q4 results. Diebold Nixdorf, Incorporated (NYSE: DBD ) gained 23.1% to $0.9746 in pre-market trading. Diebold Nixdorf confirms closing on $55 million of additional liquidity. Lixiang Education Holding Co., Ltd. (NASDAQ: LXEH ) gained 22.1% to $0.88 in pre-market trading after dropping 13% on Tuesday. Pyxis Oncology, Inc. (NASDAQ: PYXS ) rose 21.4% to $2.67 in pre-market after dropping around 7% on Tuesday. Blue Water Vaccines, Inc. (NASDAQ: BWV ) gained 16.2% to $1.22 in pre-market trading. Blue Water Vaccines recently posted upbeat FY22 earnings. Telesis Bio, Inc. (NASDAQ: TBIO ) shares rose 12.2% to $2.48 in pre-market trading following better-than-expected Q4 results.
Telesis Bio Releases BioXp Select mRNA Synthesis Kit to Expand the Utility, Speed, and Impact of Its Automated Synthetic Biology Workstation 2023/02/16 14:00:00 Wallstreet:Online
Scientists Can Now Begin the mRNA Synthesis Process from Their Own Sequence or Plasmid DNA SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the availability of its BioXp Select mRNA Synthesis Kit. This kit enables on-demand and automated synthesis of mRNA beginning from a BioXp customer’s